Climb Bio, Inc. Announces Initial PrisMN Phase 2 Data for Budoprutug in Primary Membranous Nephropathy

Climb Bio announced initial Phase 2 data from the ongoing PrisMN dose-escalation trial of budoprutug, an anti-CD19 monoclonal antibody, in primary membranous nephropathy. The excerpt identifies three dose levels—200 mg, 600 mg and 1,000 mg—but provides no efficacy or safety results.